Demorphin Raw Powder

Dermorphin raw powder is a naturally occurring heptapeptide originally isolated from the skin secretions of certain South American tree frogs. It acts as a highly selective μ-opioid receptor (MOR) agonist and has attracted considerable interest because of its distinctive structure, strong receptor-binding affinity, and relatively high metabolic stability. In its raw powder form, dermorphin is widely used in studies of opioid receptor function, pain signaling pathways, and the discovery of new therapeutic compounds. In addition, it provides a useful molecular framework for investigating biased agonism and for designing opioid-based analgesics that improve efficacy while reducing adverse effects.If you want to learn more, contact Xi'an Sonwu Biotech Co., Ltd.

Xi'an Sonwu Biotech Co., Ltd is a peptide raw material supplier with peptide technology at its core and an international market orientation. Sonwu is dedicated to the R&D, manufacturing, and worldwide distribution of bioactive peptide and polypeptide ingredients. Sonwu's products are widely applied in multiple fields, including muscle building, beauty and anti-aging, hair health, weight management, nootropics, and pharmaceutical raw materials.

Sonwu's products serve a global clientele, supporting both research and development and industrialization projects. Based on this, Sonwu has received a lot of feedback on Sonwu's products. Therefore, if you need demorphin, please contact Xi'an Sonwu.

Xi'an Sonwu not only provides large-scale production services but can also provide sample packages to customers first.

Xi'an Sonwu not only supplies high-quality demorphin, but can also customize products according to customer needs. In addition, Sonwu can provide customized packaging services, including repackaging products according to customer requirements.

1. Customized bottles(size, color, material, style)

2. Customized packaging(vacuum foil packaging, box, drum)

3. Customized label(paint film, matte film, optical mask)

Dermorphin raw powder was first reported in 1981 following the isolation and characterization of a peptide from the skin secretions of the South American tree frog Phyllomedusa sauvagei. The peptide consists of the amino acid sequence Tyr-D-Ala-Phe-Gly-Tyr-Pro-Ser-NH₂ and represents one of the earliest naturally occurring opioid peptides identified in amphibians. Several findings that emerged from subsequent studies helped establish its importance in opioid pharmacology and peptide research:

Discovery of a Unique D-Amino Acid Structure: The presence of D-alanine (D-Ala) at the second position of the sequence marked a pivotal milestone in its development. Unlike the L-amino acids commonly found in biological systems, this structural modification alters the spatial conformation of the peptide chain; this not only significantly enhances its affinity for μ-receptors but also endows the peptide with resistance against degradation by aminopeptidases, thereby resolving the industry-wide challenges associated with natural peptides-namely, their rapid metabolism and short duration of action.

2. Elucidation of Receptor Selectivity Mechanisms: SAR analyses indicate that the peptide's N-terminal sequence, Tyr-D-Ala-Phe-Gly, is critical for μ-opioid receptor binding, while the C-terminal sequence, Tyr-Pro-Ser-NH₂, enhances receptor subtype selectivity. Together, these structural features result in a μ-receptor affinity that exceeds that for δ- or κ-receptors by more than three orders of magnitude, positioning dermorphin as one of the most selective natural opioid peptides known.

3. Establishment of a Synthetic Technology Platform: Natural dermorphin can be harvested only in small quantities from raw biological materials, so extracting it directly remains expensive and impractical. To fix this supply bottleneck, research teams mostly turn to solid-phase peptide synthesis (SPPS) to ramp up output past small lab batch sizes. Developers also tweak the peptide structure and formulate it into acetate or trifluoroacetate salts; these structural adjustments improve its water solubility and shelf stability. Thanks to such refinements, the finished peptide material is far easier to source for lab testing and relevant developmental work.

The manufacturing of dermorphin raw powder strictly adheres to rigorous standards, centering on solid-phase peptide synthesis, high-efficiency purification, and aseptic processing. The entire workflow is meticulously controlled to regulate impurity levels and ensure structural integrity. The core manufacturing stages are as follows:

1. Raw Material Preparation: High-purity amino acid monomers are selected, with D-alanine serving as a critical, specialized raw material. Chiral resolution techniques are employed to ensure optical purity, thereby preventing L-isomer impurities from compromising receptor selectivity.

2.Solid-Phase Synthesis: Manufacturers perform synthesis using Rink amide resin according to standard Fmoc-based solid-phase peptide procedures. Technicians feed in individual amino acids while closely monitoring each coupling step. The entire production space remains sterile, with controlled, low oxygen levels that effectively prevent oxidation-induced breakdown of the lengthening peptide backbone.

3. Cleavage and Deprotection: Peptide cleavage and deprotection are carried out using trifluoroacetic acid (TFA). After cleavage, the crude peptide is collected through low-temperature precipitation and centrifugation. Maintaining a low processing temperature helps limit unwanted degradation and structural changes in the peptide.

4. Purification and Refinement: Purification is performed using Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC). An acetonitrile-water mobile phase is employed for gradient elution to remove impurities, and the main peak fractions are collected to ensure a final purity of ≥99%.

1. Ultra-high receptor selectivity: It can precisely target a single receptor subtype, avoiding non-specific reactions caused by receptor activation, making it an ideal tool for studying independent receptor functions.

2. Combining potency and stability: In some spinal cord analgesia models, its activity can reach hundreds of times that of morphine; at the same time, it shows strong resistance to enzymatic degradation, and its in vivo half-life is significantly longer than that of natural peptides, reducing the interference of experimental variables.

3. The structure-activity relationship: The correlation between molecular structure and receptor binding activity has been fully elucidated, providing a template for modifying and developing novel receptor ligands, assisting in the development of biased agonists, and providing insights for the design of low-side-effect opioid drugs.

4. Good drug development potential: Excellent water solubility, can cross the blood-brain barrier (in certain dosage forms), and has the potential for both central and peripheral effects; it could lead to the development of low-risk analgesic drugs.

1. Xi'an Sonwu Biotech Co . Ltd has established a complete technology platform covering peptide molecular design, custom synthesis, precision purification, structural identification, and quality control. Strictly adhering to international quality management standards, the company ensures that its peptide raw materials meet the high-end raw material requirements of overseas customers in terms of purity, stability, and batch consistency.

2. Looking to the future, Sonwu will continue to deepen peptide technology innovation, expand Sonwu's global cooperation network, and strive to become a trusted long-term peptide raw material solution partner for international customers.

Besides guaranteeing the product, the most important thing is that customers receive the goods smoothly. So, Xi'an Sonwu offers a range of couriers to meet different needs.

Based on data derived from animal experiments and research applications-and viewed strictly from the perspective of technical risk rather than clinical therapeutic risk-the potential side effects are outlined as follows:

1. Receptor-Related Reactions: Potent activation of μ-receptors may, at high doses, induce effects such as sedation, thermoregulatory dysfunction, and inhibition of gastrointestinal motility; these effects are correlated with the distribution of μ-receptors within both the central and peripheral nervous systems.

2. Neuromodulatory Risks: Prolonged or high-dose exposure may induce receptor desensitization and internalization, thereby compromising the stability of receptor signaling pathways and potentially confounding the results of experiments investigating pain mechanisms.

3. Safety and Control Requirements: Storage requires low-temperature conditions and protection from light; strict protocols must be implemented regarding the issuance and handling of the substance to prevent misuse. Furthermore, opioid receptor antagonists (e.g., naloxone) should be kept readily available during experiments to address instances of accidental exposure.

4. Absence of Human Clinical Side-Effect Data: No data on side effects in human clinical settings are currently available.

If you want to find a supplier of dermorphin, contact Xi'an Sonwu. Click the email, and then you get high-quality products.

Email: sales02@sonwu.com

Hot Tags: demorphin raw powder, China demorphin raw powder manufacturers, suppliers, factory, pharmaceutical peptides, Piperlongumine Powder, TB500 Powder